Oligonucleotide CDMO services overview- Our products

A seamless supply from research use to commercial launchHigh quality oligonucleotides
Ajinomoto Bio-Pharma Services supports your whole development stages of oligonucleotide
therapeutics. Our capability provides high quality oligonucleotides by using solid phase
synthesis and liquid phase synthesis as well.

For research use

Screening(ug)preclinical(～100 mg)

For clinical use Ac�ve Pharmaceu�cal Ingredient

Tox &formulation
study (～g)

Phase I(～200 g)

Phase II(～200 g)

Phase III(～kg)

commercial(～20 kg)

μg to kg scale custom oligonucleotide synthesis
Research to large scale synthesis

Development

 GLP-use manufacturing Analytical – GMP manufacturing
 Bridging to AJIPHASE®
 Equivalency studies
 Scale up design

Testing/Stability/validation
 Comparability studies
 Process development/Optimization

Custom Oligonucleotide manufacturing

Oligonucleotide manufacturing (by solid phase synthesis)
Offer variety of types oligonucleotides.
□ ASO□ siRNA□ CpG ODN

□ sgRNA, long chain RNA□ Aptamer□ miRNA mimic / inhibitor□ Conjugation with peptide / fluorescence□ Enzymatic conjugation

APIfor clinical use

in vitro diagnostics

Research Usematerials■ Capabilities
Small scale

Middle scale

GMP grade

Quantities

μg – mg

10 mg – 10 g

10 g – kg

SynthesizernS-8 (Original synthesizer)

OP100 & OP10

OligoProcess & OP400

Purification

HPLC

MPLC & HPLCMPLC & HPLC

DesaltingLab type

UFUF

Lyophilization

Lab type

Bulk

BulkSpecification

Ex) Purity: over 90%(RP-LC)
Endotoxin: less than 0.5 EU/mg

TBD

TBD

Details

Other options

OO

BaseO

BaseO

□ Phosphonothioate （PS）
OMeO□ 2’modification （OMe, MOE, F, etc.)

O P O□ 2’-4’bridged nucleotide （LNA/BNA/AmNA）

OMe

2’-MOE2’-OMePS□ Base modificationOOO P O□ inverted dT□ Spacer□ Terminal and/or insert modificationetc.

OBaseOOOO P O

OBaseOO N O
RO P OOOBaseOO

NO P O

R=H ,MeLNA

BNA

AmNA

MeAJIPHASE®
Innovative liquid phase synthesis for oligonucleotide, peptide,
PMO and PPMO; AJIPHASE®
AJIPHASE® is a hybrid of solid and solution phase syntheses that uses an anchor to make themolecules very soluble in non-polar solvents, providing a homogenous mixture.
□ Mass production with High quality□ High reproductivity□ Seamless scale up from lab to commercial

FDA approval

Green Chemistry

Functional conjugation
Functional conjugation[Options]□ fluorescence, quencher

a. Amino oligo + NHS ester compoundPurple：Alexa750, Cy7

Red：Alexa647, Alexa 594, Cy5

Orange：Alexa568

Yellow：Alexa546, Cy3, TAMRA

b. Thiol oligo + Maleimide compoundc. Thiol oligo ＋ Thiol compoundd. DBCO oligo + Azide compound

Yellow green :Alexa532
Yellow blue

:Alexa488, BODIPY FL, 6-FAM

QuencherOligo

Oligo：BHQ，Dabcyl
Oligo□ ５’end or ３’end phosphorylation

Oligo□ Biotin□ Cholesterol, Tocopherol，DIG

Oligo

Oligo

□ PEG （liner，branch）□ Peptide,etc.
Oligo
Oligo

Analytical services□ Methods development□ Method verification/validation□ Stability studies□ Contracted analysis
Purity (RP-LC)
Tm value
Water content （KF）
Confirm quality
Endotoxin
NMR

sequencing
Identification

ICP

ESI-MS

Please contact us if you request other ten above test items.

Other services
CpG-ODN
The sequences contain CpG motif which induces strong innate immunity.
It activates innate immunity by being recognized by Toll-Like receptor9 (TLR9).

As adjuvant

DNA fragment includes CpG motif

Ｄ３５ （Type-A/D CpG-ODN）

K3 （Type-B/K CpG-ODN）□ Target cell： pDCｓ

□ Target cell： B cell

□ Induced cytokines： IFN-α□ Induced cytokines ： IL-6, other［Structure of DNA fragment］［Structure of DNA fragment］

PS partly

Full PS

Hairpin structure

Liner structure

poly G tail, palindrome

5’3’5’3’

Contact toAjinomoto Bio-Pharma Services
GeneDesign, Inc.
7-7-29 Saitoasagi Ibaraki, Osaka
567-0085, JAPAN
TEL：+81-72-640-5180
E-mail：gdi_info@jp.ajibio-pharma.com
URL：https://www.ajioligos.com

NoteThe specification and prices are subject to change without notice.
As Jun 2023